David Hastings

Mr. Hastings joined the board in September 2015. He currently serves as the Chief Financial Officer at Arbutus Biopharma Corp. (Nasdaq: ABUS). Prior to joining Arbutus in June 2018, Mr. Hastings served as the Senior Vice President and Chief Financial Officer of Unilife Corporation from February 2015 to June 2017. From October 2003 to October 2014, he served as Executive Vice President and Chief Financial Officer at Incyte Corporation (Nasdaq: INCY). From February 2000 to September 2003, Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule, Inc. (Nasdaq: ARQL). Prior to his employment with ArQule and from June 1997 to February 2000, Mr. Hastings was Vice President and Corporate Controller at Genzyme, Inc. (Nasdaq: GENZ), where he was responsible for the management of the finance department. Prior to his employment with Genzyme and from May 1994 to June 1997, Mr. Hastings was the Director of Finance at Sepracor, Inc., where he was primarily responsible for Sepracor's internal and external reporting. He currently serves as a member of the board of directors of VBL Therapeutics (Nasdaq: VBLT) and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX). Mr. Hastings received his B.A. in Economics at the University of Vermont.